Peripheral T-cell lymphoma unspecified – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peripheral T-cell lymphoma unspecified – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas https://clinicaltrials.eu/trial/study-on-azacitidine-roginolisib-and-golcadomide-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ Wed, 29 Apr 2026 15:05:07 +0000 https://clinicaltrials.eu/trial/study-on-azacitidine-roginolisib-and-golcadomide-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ This clinical trial is focused on studying new treatments for a type of cancer called Peripheral T-Cell Lymphoma that has either returned after treatment or has not responded to previous treatments. The study will explore the effects of several medications, including Azacitidine, IOA-244 (also known as Roginolisib), and Golcadomide (also referred to by its code name CC-99282). These medications are being tested to see if they can improve outcomes for patients with this challenging condition.

The purpose of the study is to determine the safety and tolerability of these medications, as well as to identify the most effective doses. The study will be conducted in two phases. In the first phase, researchers will focus on finding the safest dose of the medications by gradually increasing the dose and monitoring for any side effects. In the second phase, the study will aim to identify which of these medications, or combinations of them, can significantly improve the condition of patients with relapsed or refractory Peripheral T-Cell Lymphoma.

Participants in the study will receive one or more of the study medications in the form of tablets or capsules, taken orally. The study will monitor participants over time to assess how well the medications are working and to check for any side effects. The ultimate goal is to find new and effective treatment options for patients with this type of lymphoma, improving their quality of life and potentially extending their survival.

]]> Study on the Effectiveness and Safety of Belinostat and Pralatrexate with Drug Combination for Newly Diagnosed Peripheral T-Cell Lymphoma Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-belinostat-and-pralatrexate-with-drug-combination-for-newly-diagnosed-peripheral-t-cell-lymphoma-patients/ Wed, 29 Apr 2026 15:01:37 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-belinostat-and-pralatrexate-with-drug-combination-for-newly-diagnosed-peripheral-t-cell-lymphoma-patients/ This clinical trial is focused on studying a type of blood cancer called Peripheral T-Cell Lymphoma (PTCL). The study aims to evaluate the safety and effectiveness of different treatment combinations for patients who have been newly diagnosed with this condition. The treatments being tested include a combination of drugs known as Bel-CHOP and Fol-COP. The Bel-CHOP regimen includes the drug Belinostat along with a standard chemotherapy regimen called CHOP, which consists of Cyclophosphamide, Doxorubicin, Vincristine Sulfate, and Prednisone. The Fol-COP regimen includes the drug Pralatrexate combined with a modified version of the CHOP regimen, excluding Doxorubicin.

The purpose of the study is to determine which treatment combination is more effective in improving the progression-free survival of patients, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will be conducted in two parts. The first part will focus on finding the best dose levels for Belinostat and Pralatrexate when used with the CHOP regimen. The second part will compare the effectiveness and safety of the Bel-CHOP and Fol-COP combinations against the CHOP regimen alone. Patients will receive treatment for up to six cycles, and their health will be monitored to assess the outcomes.

Participants in the study will receive their treatments through intravenous methods, which means the medication will be delivered directly into a vein. The study will also involve regular check-ups and assessments to monitor the patients’ response to the treatment and any side effects they may experience. The ultimate goal is to find a more effective treatment option for patients with newly diagnosed Peripheral T-Cell Lymphoma, potentially improving their quality of life and survival rates.

]]> Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma https://clinicaltrials.eu/trial/study-of-lacutamab-gemcitabine-and-oxaliplatin-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/ Wed, 29 Apr 2026 15:00:51 +0000 https://clinicaltrials.eu/trial/study-of-lacutamab-gemcitabine-and-oxaliplatin-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called Peripheral T-Cell Lymphoma (PTCL), which is a rare and aggressive form of non-Hodgkin lymphoma. The study is specifically for patients whose cancer has returned or has not responded to previous treatments. The trial will test a new treatment approach using a medication called Lacutamab, also known by its code name IPH4102, in combination with two chemotherapy drugs, Gemcitabine and Oxaliplatin, collectively referred to as GemOx. The purpose of the study is to evaluate how effective Lacutamab is when used with GemOx compared to using GemOx alone.

Participants in the study will be randomly assigned to receive either the combination of Lacutamab with GemOx or GemOx alone. Lacutamab is a type of protein-based treatment known as a monoclonal antibody, which is designed to target specific cancer cells. Gemcitabine and Oxaliplatin are chemotherapy drugs that work by stopping the growth of cancer cells. The treatment will be given through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will monitor the participants over a period to see how the cancer responds to the treatment and to assess the safety and potential side effects of the medications.

The trial aims to provide valuable information on whether adding Lacutamab to the standard GemOx treatment can improve outcomes for patients with relapsed or refractory Peripheral T-Cell Lymphoma. This study is important for understanding new ways to treat this challenging disease and may help in developing more effective treatment options in the future.

]]> Study on the Safety and Effects of Tolinapant in Patients with Advanced Solid Tumors and Lymphomas https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolinapant-in-patients-with-advanced-solid-tumors-and-lymphomas/ Wed, 29 Apr 2026 14:59:44 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolinapant-in-patients-with-advanced-solid-tumors-and-lymphomas/ This clinical trial is focused on studying the effects of a medication called Tolinapant, also known by its code name ASTX660. The study is aimed at people with advanced forms of cancer, specifically solid tumors and lymphomas. These are types of cancers that have either spread to other parts of the body or cannot be removed through surgery. The specific types of cancer being studied include head and neck cancer, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, and cervical cancer, among others.

The purpose of the study is to evaluate the safety and effectiveness of Tolinapant in treating these advanced cancers. Participants in the study will receive the medication in the form of a capsule taken by mouth. The study will be conducted in phases, with the first phase already completed. The second phase will focus on assessing how well the medication works in reducing the size of tumors or slowing their growth. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Tolinapant.

Throughout the study, participants will be monitored for any side effects and changes in their condition. The study aims to determine the best dose of Tolinapant and to gather information on how the body processes the medication. This information will help researchers understand the potential benefits and risks of using Tolinapant as a treatment for advanced cancers. The study is expected to continue until the end of 2025.

]]> Study on Brentuximab Vedotin and Drug Combination for Patients with Peripheral T-cell Lymphoma with Less Than 10% CD30 Expression https://clinicaltrials.eu/trial/study-on-brentuximab-vedotin-and-drug-combination-for-patients-with-peripheral-t-cell-lymphoma-with-less-than-10-cd30-expression/ Wed, 29 Apr 2026 14:25:40 +0000 https://clinicaltrials.eu/trial/study-on-brentuximab-vedotin-and-drug-combination-for-patients-with-peripheral-t-cell-lymphoma-with-less-than-10-cd30-expression/ This clinical trial is focused on studying a type of cancer called Peripheral T-cell Lymphoma (PTCL). The study is investigating a treatment combination that includes several medications: Brentuximab Vedotin, Doxorubicin Hydrochloride, Cyclophosphamide, and Prednisone. These medications are used to treat cancer by targeting and killing cancer cells. The purpose of the study is to evaluate how well this combination works in treating PTCL, especially in cases where the cancer cells have less than 10% of a protein called CD30.

Participants in the study will receive the treatment over a period of six months. The treatment involves receiving the medications through an intravenous infusion, which means the drugs are given directly into a vein, and in the case of prednisone, it is taken orally as a tablet. The study is designed to observe the response of the cancer to the treatment and to monitor any side effects that may occur. The study will also look at how long the treatment keeps the cancer from getting worse and the overall survival of the participants.

The study is open-label, meaning both the researchers and participants know which treatment is being given. It is divided into two groups, or cohorts, to better understand the effects of the treatment. The results will be reviewed by independent experts to ensure accuracy. This study aims to provide valuable information on the effectiveness of this treatment combination for people with PTCL, potentially leading to improved treatment options in the future.

]]> Study on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination https://clinicaltrials.eu/trial/study-on-the-benefits-of-autologous-stem-cell-transplantation-for-patients-with-peripheral-t-cell-lymphoma-using-etoposide-and-drug-combination/ Wed, 29 Apr 2026 14:24:37 +0000 https://clinicaltrials.eu/trial/study-on-the-benefits-of-autologous-stem-cell-transplantation-for-patients-with-peripheral-t-cell-lymphoma-using-etoposide-and-drug-combination/ This clinical trial is focused on studying a type of cancer called Peripheral T-cell lymphoma (PTCL). The trial is investigating the potential benefits of a treatment called autologous stem cell transplantation (ASCT) for patients who have achieved a complete response after initial chemotherapy. The study aims to determine if this treatment can help prolong the time patients remain free from cancer progression.

Participants in the study will receive a combination of medications as part of their treatment. These medications include Etoposide, Methylprednisolone, Prednisone, Brentuximab vedotin, Doxorubicin, Vincristine, and Cyclophosphamide. Some of these medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein, while others are taken orally as tablets or capsules. The study also involves the use of a placebo for comparison purposes.

The trial will follow participants over a period of time to monitor their response to the treatment and to assess the duration of their response. The goal is to gather information on how effective the treatment is in extending the time patients remain free from cancer progression and to evaluate overall survival rates. This study is an important step in understanding how to improve treatment outcomes for patients with Peripheral T-cell lymphoma.

]]> Study of Romidepsin and Drug Combination for Young Patients with Peripheral T-Cell Lymphomas Before Stem Cell Transplantation https://clinicaltrials.eu/trial/study-of-romidepsin-and-drug-combination-for-young-patients-with-peripheral-t-cell-lymphomas-before-stem-cell-transplantation/ Wed, 29 Apr 2026 14:22:38 +0000 https://clinicaltrials.eu/trial/study-of-romidepsin-and-drug-combination-for-young-patients-with-peripheral-t-cell-lymphomas-before-stem-cell-transplantation/ This clinical trial is focused on studying certain types of lymphoma, which is a cancer of the lymphatic system. The specific types being studied are Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, and Peripheral T-cell Lymphoma, NOS. The treatment being tested is a combination of a drug called Romidepsin and a chemotherapy regimen known as CHOEP. Romidepsin is a type of medication that is given as a solution for injection and works by inhibiting certain enzymes in cancer cells, which may help to stop their growth.

The purpose of this study is to evaluate the safety and effectiveness of this treatment combination as a first-line therapy before a procedure called hematopoietic stem cell transplantation, which is a type of treatment that replaces damaged or destroyed bone marrow with healthy bone marrow stem cells. The study is divided into two phases. In the first phase, the focus is on determining the safest dose of the treatment combination. In the second phase, the study aims to assess how well the treatment works in terms of preventing the cancer from getting worse or coming back.

Participants in the study will receive the treatment combination and will be monitored over time to see how their cancer responds to the treatment. The study will also look at the overall response rate, which measures how many patients experience a reduction in cancer size or symptoms, and the overall survival rate, which tracks how long patients live after starting the treatment. The study is expected to continue until March 2025, with ongoing assessments to ensure the safety and effectiveness of the treatment.

]]>